Rtw Investments Adds $257M in Celcuity Inc. ($CELC)

RTW Investments has made a substantial increase in its stake in Celcuity Inc. (NasdaqCM: CELC), according to the latest Form 13F filing with the SEC. The investment firm boosted its holdings by approximately 2,489,461 shares, raising its total to 3,039,621 shares. This represents an increase of about 452%, with the position now valued at roughly $272 million, as of the reporting period.

What Changed in RTW Investments's Celcuity Position

RTW Investments significantly expanded its position in Celcuity Inc. by adding about 2.5 million shares, growing its stake by 452% to a total of 3,039,621 shares. The reported value of this holding is approximately $272 million. Before this increase, RTW held 550,160 shares.

Other Institutional Activity in Celcuity

Other institutional investors also showed interest in Celcuity. Baker Bros. Advisors LP maintained its position with 7,915,792 shares valued at about $903.5 million. Avoro Capital Advisors LLC increased its holdings by 263,889 shares, reaching a total of 3,375,000 shares worth approximately $385.2 million. Perceptive Advisors LLC slightly reduced its position by 33,000 shares, now holding 3,127,200 shares valued at $356.9 million. Meanwhile, NEA Management Company, LLC decreased its stake by 1,250,000 shares to 2,285,561 shares, valued at approximately $260.9 million.

Celcuity Inc. Stock Up 16.8%

Shares of Celcuity Inc. (NasdaqCM: CELC) are trading around $89.49. The company has a market cap of about $4.32 billion and a forward P/E ratio of 119.66. With a beta of 0.118, the stock has shown a 52-week low of $11.28 and a high of $151.02. Its 50-day moving average is $120.20, while the 200-day moving average stands at $96.67. The company's current ratio is 12.313, with a quick ratio of 11.655 and a debt-to-equity ratio of 604.28.

Recent Earnings

Celcuity Inc. reported a net margin of 0.0 and a return on equity of -2.75. The company is not currently profitable, as indicated by its negative EPS of -3.9. The next earnings report is expected on May 14, 2026.

Insider Buying and Selling at Celcuity Inc.

Recent insider activity at Celcuity includes transactions by Richard Buller and Polly Murphy. On June 10, 2026, Richard Buller sold and bought 12,503 shares, while Polly Murphy executed similar buy and sell transactions on the same day. Additionally, both insiders purchased 1,530 shares each on June 5, 2026.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on Celcuity. On June 3, 2026, Craig-Hallum, Wells Fargo, and HC Wainwright & Co. each maintained a 'buy' rating, with price targets of $171, $166, and $145, respectively. The consensus among analysts is a 'strong buy,' with a mean target price of $161.09 based on 11 opinions.

About Celcuity Inc.

Celcuity Inc. is a biotechnology company based in Minneapolis, Minnesota. It focuses on developing targeted therapies for solid tumors. The company's leading drug candidate, Gedatolisib, targets specific pathways for treating advanced or metastatic breast cancer and prostate cancer. Celcuity was incorporated in 2011 and is led by CEO Brian F. Sullivan. The company employs around 155 people.

Bottom Line

RTW Investments' significant increase in its stake in Celcuity highlights the firm's strong interest in the biotechnology company's potential. Investors track such filings to gauge institutional confidence, although it's important to note these filings reflect past positions and may not represent current holdings. With a strong buy consensus from analysts, Celcuity remains a company to watch in the healthcare sector.